Boston Scientific (BSX) stock
Health Care · Health Care Equipment
Boston Scientific (BSX) is a Health Care Equipment company in the Health Care sector, headquartered in Marlborough, Massachusetts. As of October 23, 2026, BSX closed at $45.69, a market capitalization of $66.22 billion, the 187th largest company in the S&P 500. Over the last twelve months it generated $21.00 billion in revenue (+8% year over year) and $1.81 billion in free cash flow. The stock trades at 18.5x trailing earnings and 13.5x forward earnings.
- 1-year total return: -55.4% (dividends reinvested)
- 5-year return: +0.4% a year
- 52-week range: $41.39 – $105.65
- Gross margin 69.2%, operating margin 22.9%
- FI Handbook report card: C+ across 10 metrics
- 24th largest of 60 Health Care stocks in the S&P 500
BSX price chart
1Y price change: -55.4% (price only; total returns below include dividends)
| Total return | 1M | YTD | 1Y | 3Y | 5Y | 10Y | MAX |
|---|---|---|---|---|---|---|---|
| BSX | +2.4% | -52.1% | -55.4% | -3.0% | +0.4% | +7.2% | +7.1% |
Dividends reinvested. 3Y and longer are annualized; MAX is annualized since 1992.
BSX key statistics
- Market cap
- $66.2B
- #187 in S&P 500
- P/E (TTM)
- 18.5x
- Forward P/E
- 13.5x
- EPS (TTM)
- $2.47
- Revenue (TTM)
- $21.0B
- +8%
- Free cash flow
- $1.8B
- Gross margin
- 69.2%
- Operating margin
- 22.9%
- Return on equity
- 15.3%
- Dividend yield
- None
- 52-week range
- $41.39 – $105.65
- Beta
- 0.57
- Price / sales
- 3.2x
- EV / EBITDA
- 13.8x
- Debt / equity
- 0.50x
- Employees
- 59,000
BSX report card
C+Ten fundamentals graded A to F against fixed thresholds. Not a buy or sell rating.
- Revenue growth7.5%C
- Gross margin69.2%A
- Operating margin22.9%B
- FCF margin8.6%C
- Return on equity15.3%B
- Net debt / EBITDA2.1xD
- Forward P/E13.5xA
- PEG ratio0.6xA
- Shareholder yield0.0%F
- Share count change / yr1.1%D
Boston Scientific financials
Revenue went from $8.4B in fiscal 2016 to $20.1B in fiscal 2025, growing 10.2% a year.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.4B | $9.0B | $9.8B | $10.7B | $9.9B | $11.9B | $12.7B | $14.2B | $16.7B | $20.1B |
| Gross profit | $6.0B | $6.5B | $7.0B | $7.6B | $6.4B | $8.2B | $8.7B | $9.9B | $11.5B | $13.9B |
| Operating income | $447.0M | $1.3B | $1.5B | $1.5B | -$80.0M | $1.2B | $1.6B | $2.3B | $2.6B | $3.6B |
| Net income | $347.0M | $104.0M | $1.7B | $4.7B | -$82.0M | $1.0B | $698.0M | $1.6B | $1.8B | $2.9B |
| EPS (diluted) | $0.25 | $0.08 | $1.19 | $3.33 | $-0.08 | $0.69 | $0.45 | $1.07 | $1.25 | $1.94 |
| Free cash flow | $806.0M | $1.1B | -$6.0M | $1.4B | $1.1B | $1.3B | $938.0M | $1.8B | $2.6B | $3.7B |
| Buybacks | $0 | — | $0 | $0 | $535.0M | $0 | $0 | — | — | — |
| Dividends paid | — | — | $0 | $0 | $28.0M | $55.0M | $55.0M | $28.0M | $0 | — |
| Diluted shares | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.4B | 1.5B | 1.5B | 1.5B |
Source: SEC filings (10-K XBRL). EPS and share counts are split-adjusted.
What's priced into BSX?
A reverse DCF asks what growth the current price requires. With an enterprise value of $78.3B and $1.8B of trailing free cash flow, Boston Scientific needs to grow free cash flow about 30.6% a year for ten years (fading to 3.0% terminal growth) to earn a 10% annual return. For context, free cash flow grew 26.4% a year over the last five years.
P/E ratio history
Current 23.6x vs. median 67.1x (10th–90th percentile 15.6x–220.9x).
A model, not a forecast or advice. Small changes in assumptions move the answer a lot.
BSX analyst price targets
28 analysts' average 12-month target is $57.82 (+27% vs. $45.69). Targets range from $44.00 to $78.00. 80% rate it a buy.
BSX earnings
Next report: October 28, 2026. Boston Scientific has beaten EPS estimates 8 quarters in a row. Last quarter's revenue was $5.4B (+8% year over year).
| Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Jul 29, 2026 | $0.83 | $0.86 | +3.9% |
| Apr 22, 2026 | $0.79 | $0.80 | +1.6% |
| Feb 4, 2026 | $0.78 | $0.80 | +2.4% |
| Oct 22, 2025 | $0.71 | $0.75 | +5.1% |
| Jul 23, 2025 | $0.73 | $0.75 | +3.4% |
| Apr 23, 2025 | $0.67 | $0.75 | +11.5% |
| Feb 5, 2025 | $0.66 | $0.70 | +6.6% |
| Oct 23, 2024 | $0.59 | $0.63 | +7.0% |
Stocks like BSX
| Name | Today | 1Y | Mkt cap | P/E | |
|---|---|---|---|---|---|
 ABT Abbott Laboratories | +1.16% | -16% | $179.4B | 38.6x | Compare |
 ISRG Intuitive Surgical | +1.90% | -18% | $159.8B | 54.7x | Compare |
 MDT Medtronic plc. | -1.22% | +5% | $122.0B | 23.4x | Compare |
 SYK Stryker | +0.02% | -19% | $117.8B | 31.8x | Compare |
 BDX Becton, Dickinson and | -0.75% | +39% | $54.2B | 46.3x | Compare |
 EW Edwards Lifesciences Corporatio | -1.13% | +16% | $51.3B | 53.0x | Compare |
 IDXX IDEXX Laboratories | -1.13% | -12% | $44.1B | 39.4x | Compare |
 RMD ResMed | -0.08% | -4% | $35.6B | 24.2x | Compare |
BSX news
- Pacemakers Market Forecasts Growth from $5.4 Billion (2025) to $7.5 Billion by 2030, Profiling Medtronic, Abbott, Boston Scientific, Biotronik & 6 Other Key Players · Oct 23, 2026
- Insights Into Boston Scientific (BSX) Q3: Wall Street Projections for Key Metrics · Oct 23, 2026
- Boston Scientific (BSX) Stock May Be 44% Undervalued As Neuromodulation Growth Builds · Oct 22, 2026
- Australia Bionic Devices Market Size, Share, Growth, and Forecast 2026-2034 Featuring Profiles of Cochlear, Medtronic Australasia, Edwards Lifesciences Australia, Baxter Int'l, Boston Scientific Corp., Abiomed Australia, Abbott Labs · Oct 22, 2026
- Global Gastric Device Market Report 2026-2032: Size, Share, Trends and Forecast for Gastric Bands and Balloons | GLP-1 Drugs Leave Gastric Balloons and Bands Struggling for Growth · Oct 22, 2026
BSX stock FAQ
What is BSX's market cap?
Boston Scientific's market capitalization is $66.22 billion as of October 23, 2026, ranking 187th in the S&P 500.
What is BSX's P/E ratio?
BSX trades at a trailing price-to-earnings ratio of 18.5x and a forward P/E of 13.5x. Its median P/E over the period we track is 67.1x.
Does BSX pay a dividend?
No. Boston Scientific does not currently pay a regular cash dividend.
How much has BSX stock returned?
Including reinvested dividends, BSX returned -55.4% over one year, +0.4% a year over five years, +7.2% a year over ten years through October 23, 2026.
Is BSX stock overvalued?
At today's price, a reverse discounted cash flow model (10% discount rate, 3% terminal growth) implies Boston Scientific must grow free cash flow about 31% a year for the next decade. Its free cash flow grew 26% a year over the last five years. Whether that is achievable decides if the stock is cheap or expensive. This is a model, not advice.
What is the BSX price target?
28 analysts cover BSX with an average 12-month price target of $57.82, +27% from the current price. 80% of them rate it a buy.
When does BSX report earnings?
Boston Scientific is expected to report earnings on October 28, 2026. It has beaten EPS estimates 8 quarters in a row.
How many employees does Boston Scientific have?
Boston Scientific has about 59,000 full-time employees, or $355,864 of revenue per employee.
Sources: SEC EDGAR filings, Yahoo Finance market data (delayed), FI Handbook calculations. Last close October 23, 2026. Methodology